Aethlon Medical (AEMD) to Release Quarterly Earnings on Thursday

Aethlon Medical (NASDAQ:AEMD) will likely be posting its Q3 2026 results after the market closes on Thursday, February 12th. Analysts expect Aethlon Medical to post earnings of ($2.01) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($2.04). On average, analysts expect Aethlon Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aethlon Medical Stock Down 1.3%

Shares of Aethlon Medical stock opened at $2.20 on Wednesday. The firm has a market cap of $2.14 million, a PE ratio of -0.10 and a beta of 1.60. Aethlon Medical has a 12-month low of $2.08 and a 12-month high of $55.62. The company’s fifty day simple moving average is $2.82 and its two-hundred day simple moving average is $6.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Aethlon Medical has a consensus rating of “Reduce” and an average price target of $560.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.